Activist investor Starboard Value has taken a substantial stake of approximately $1 billion in Pfizer, aiming to instigate a turnaround at the pharmaceutical company, which has faced financial struggles despite its pandemic-driven revenue boost. The exact details of Starboard’s plans remain unclear, but the hedge fund has reportedly approached former Pfizer executives Ian Read, the… Continue reading Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say

BioNxt Solutions Inc. (“BioNxt” or the “Company“) (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings decades of start-up and emerging growth capital markets experience in the resource and bioscience sectors, including finance and M&A, as well as an extensive and influential… Continue reading Terry Lynch Joins BioNxt as Capital Markets Advisor

BioNxt is striving to have a positive impact on global health The company is creating potentially life-changing solutions through research, development and collaboration.  Bionxt Solutions (CSE:BNXT) works with promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility. The… Continue reading BioNxt Solutions Inc. (CSE: BNXT / OTC: BNXTF / FSE: BXT) – Rapidly innovating the drug formulation, drug delivery and neurological drugs and working to become the single largest biotech phenomenon trading in Canada

Eli Lilly is making a major investment of $4.5 billion to build the Lilly Medicine Foundry, a facility dedicated to innovating and improving drug manufacturing processes. This center, which is expected to open in late 2027, will focus on developing more efficient methods for producing medicines, including small molecules, biologics, and genetic treatments. The foundry… Continue reading Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline

TORONTO, Ontario, Oct. 02, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that following its annual general meeting held on September 30, 2024 (the “Meeting”) and in accordance with Titan’s Majority Voting Policy (the “Voting Policy”), Anthony Giovinazzo, Cathy Steiner, Cary Vance and Paul Cataford have tendered to the Board… Continue reading Titan Announces Resignations of Directors

Glenview Capital, a significant shareholder in CVS Health, is scheduled to meet with the company’s leadership to discuss potential strategies for revitalizing the struggling business, which may signal an impending activist campaign. Glenview has built a substantial position in CVS alongside its investments in other healthcare companies like Centene and Teva Pharmaceuticals. Although specific details… Continue reading Major CVS shareholder plans activist push, will meet with management, sources say

CVS Health is currently undergoing a strategic review of its business in light of declining stock prices and potential activist pressure, according to sources familiar with the situation. Although this review has been in progress for some time, it remains uncertain what actions may be taken, with the possibility of breaking up the company’s insurance… Continue reading CVS is working with advisors on strategic review, sources say

A recent article in CNBC’s Healthy Returns newsletter highlights that Wegovy, Novo Nordisk’s popular weight loss drug, is a top contender for the second round of price negotiations between drug manufacturers and Medicare. The upcoming negotiations, set to unveil the next 15 costliest Medicare Part D drugs by February, aim to reduce prices for medications,… Continue reading Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next

A recent study published in JAMA Network Open has found that Novo Nordisk’s diabetes medication Ozempic, which contains the active ingredient semaglutide, may significantly reduce the risk of opioid overdoses in patients who have both Type 2 diabetes and opioid use disorder. This finding highlights Ozempic’s potential as an alternative treatment option amid the ongoing… Continue reading Novo Nordisk’s diabetes drug Ozempic may lower the risk of opioid overdoses, study says

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research collaboration aimed at leveraging each company’s expertise… Continue reading Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief… Continue reading BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024

Pfizer has announced promising results from a mid-stage clinical trial for its experimental drug, ponsegromab, designed to treat cancer cachexia, a debilitating condition characterized by severe weight and muscle loss in cancer patients. This condition affects around 9 million people globally and is linked to poor outcomes, with 80% of cancer patients suffering from cachexia… Continue reading Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results